🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,418 results for “1” Clear

  1. ADX-2191 (intravitreal methotrexate 0.8%)

    Aldeyra Therapeutics

    Proliferative Vitreoretinopathy

    phase 3 small molecule completed

    1 trial

  2. AG-120/S95031 250mg film-coated tablet, Ivosidenib-matched Placebo Tablets

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 or 2 systemic treatment regimens

    phase 3 small molecule active

    1 trial

  3. AG10

    BridgeBio Oncology Therapeutics

    Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy

    phase 3 small molecule terminated

    1 trial

  4. AK112 Injection

    Summit Therapeutics

    Non-Squamous Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  5. ALIMTA 500 mg powder for concentrate for solution for infusion, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, ALIMTA 500 mg powder for concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion, Pembrolizumab, KEYTRUDA 25 mg/m

    Celltrion Healthcare Hungary Kft.

    Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  6. ALKS 2680, ALKS 2680, ALKS 2680, ALKS 2680, ALKS 2680, ALKS 2680

    Alkermes Pharma Ireland

    Narcolepsy Type 1, Type 2 and Idiopathic Hypersomnia

    phase 3 small molecule active

    1 trial

  7. ALPELISIB, ALPELISIB, ALPELISIB

    Cancer Prevention Pharma (Ireland) Limited

    PIK3CA mutated HER2+ advanced or relapsed breast cancer (BC) previously treated with trastuzumab

    phase 3 small molecule active

    1 trial

  8. ALPELISIB, FULVESTRANT, ALPELISIB, Placebo to BYL719 50 mg film-coated tablet Light pink Placebo to BYL719 200 mg film-coated tablet Light red

    Novartis Ophthalmics Europe

    Hormone receptor positive, HER2-negative advanced breast cancer

    phase 3 small molecule active

    1 trial

  9. ALTUVOCT 2 000 IU powder and solvent for solution for injection, ALTUVOCT 3 000 IU powder and solvent for solution for injection, ALTUVOCT 4 000 IU powder and solvent for solution for injection, ALTUVOCT 250 IU powder and solvent for solution for injection, ALTUVOCT 1 000 IU powder and solvent for solution for injection, ALTUVOCT 500 IU powder and solvent for solution for injection

    Swedish Orphan Biovitrum AB (publ)

    Haemophilia A

    phase 3 small molecule active

    1 trial

  10. ALVAC-HIV vCP1521 + AIDSVAX

    United Therapeutics Europe Ltd

    HIV Infection

    phase 3 mab completed

    1 trial

  11. ALX1-11

    Takeda Pharmaceuticals International AG

    Osteoporosis

    phase 3 small molecule completed

    1 trial

  12. ALX1-11 (drug)

    Takeda Pharmaceuticals International AG

    Osteoporosis

    phase 3 small molecule completed

    1 trial

  13. ALXN1720 Placebo Product, Gefurulimab

    Alexion Europe SAS

    Generalized Myasthenia Gravis with autoantibodies against acetylcholine receptor (AChR)

    phase 3 small molecule active

    1 trial

  14. ALXN1850 placebo product, ALXN1850

    Alexion Europe SAS

    Hypophosphatasia

    phase 3 small molecule active

    1 trial

  15. ALXN1850, ALXN1850 placebo product

    Alexion Europe SAS

    hypophosphatasia

    phase 3 small molecule active

    1 trial

  16. ALXN1850, Strensiq 40 mg/ml Solution for Injection, Strensiq 100 mg/ml Solution for Injection

    Alexion Europe SAS

    Hypophosphatasia

    phase 3 small molecule active

    1 trial

  17. ALXN2220 Placebo Product, Recombinant human anti-ATTR immunoglobulin G1 (IgG1) monoclonal antibody (mAb)

    Alexion Europe SAS

    Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM).

    phase 3 small molecule active

    1 trial

  18. AMG 133, AMG 133, AMG 133, AMG 133, Placebo for Maridebart cafraglutide

    Amgen Technology (Ireland) UC

    Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweight

    phase 3 small molecule active

    1 trial

  19. AMG 133, Placebo for AMG 133 (maridebart cafraglutide)

    Amgen Technology (Ireland) UC

    Chronic Weight Management

    phase 3 small molecule active

    1 trial

  20. AMG 133, Placebo for AMG 133, AMG 133, AMG 133

    Amgen Technology (Ireland) UC

    "Moderate to severe obstructive sleep apnea (OSA) in adults living with overweight or obesity"

    phase 3 small molecule active

    1 trial

  21. AMG 133, Placebo for Maridebart Cafraglutide

    Amgen Technology (Ireland) UC

    Chronic Weight Management

    phase 3 small molecule active

    1 trial

  22. AMIKACIN

    Pari Pharma GmbH

    Adult patients admitted to intensive care

    phase 3 small molecule active

    1 trial

  23. AMIKACINE VIATRIS 1 g, poudre pour solution injectable en flacon, CHLORURE DE SODIUM 0,9 % COOPER, solution pour perfusion

    Tour Hekla

    Patients with ventilator-associated tracheobronchitis

    phase 3 small molecule active

    1 trial

  24. AMOXICILLIN TRIHYDRATE, SULFAMETHOXAZOLE AND TRIMETHOPRIM , LEVOFLOXACIN, AMOXICILLIN , AZITHROMYCIN, AZITHROMYCIN , IMMUNOGLOBULINS, NORMAL HUMAN, FOR INTRAVASCULAR ADM., LEVOFLOXACIN

    Pari Pharma GmbH

    Young Adults and adults with R/R B-cell acute lymphoblastic leukemia (BCP-ALL) or a B cell lymphoma (BCL)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources